Psilocybin Study: Digital Intervention for Psychedelic Preparedness (DIPP)
10 December 2024
The DIPP study explores psilocybin's effects on well-being and cognition through a 21-day digital preparation program. Healthy participants complete daily reflective and mindfulness exercises before a supervised psilocybin session. The study involves four in-person visits at UCL: baseline assessments, pre-dosing tasks, dosing day, and follow-up. Participants provide voice notes and complete surveys over nine months. Psilocybin is safely administered in a controlled setting at UCL, London.
Requirements
- Aged 21–65 years.
- Limited psychedelic use (0–5 high-dose sessions; none in the past 6 months).
- Minimal meditation experience (≤10 sessions; no retreats or regular practice).
- Native English speaker.
- Normal or corrected-to-normal colour vision.
- Able and willing to provide informed consent.
- Able to engage with all study requirements, including in-person and remote sessions.
- UK resident registered with a primary care practice.
- Agree to allow research team contact with primary/secondary care teams if needed.
- Access to electronic devices for data entry.
- No current or past psychotic or bipolar disorder.
- No immediate family member with psychotic or bipolar disorder.
- No suicidal ideation or any attempts.
- No medically significant conditions (e.g., cardiovascular disease, uncontrolled hypertension).
- No use of medications interacting with psilocybin (e.g., antipsychotics, SSRIs, SNRIs, TCAs, mood stabilizers).
- No psychoactive drug use within 30 days (except nicotine or caffeine).
- No pregnancy, planning pregnancy, or breastfeeding.
- No participation in a drug trial within 6 months.
- No MRI contraindications (e.g., metal implants, pacemakers, severe claustrophobia).
- No medical contraindications (e.g., epilepsy, migraines, focal scalp sensitivity).
Keywords
Ethical approval
Study approved by UCL Research Ethics Committee.
